Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA™ (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. Eli Lilly and Co (NYSE:LLY) shares after opening at $60.44 moved to $60.89 on last trade day and at the end of the day closed at $60.86. Company price to sales ratio in past twelve months was calculated as 2.95 and price to cash ratio as 12.63. Eli Lilly and Co (NYSE:LLY) showed a positive weekly performance of 4.12%.
Kenneth B. Lee, Jr., a member of the Board of Directors of POZEN Inc (NASDAQ:POZN) and Chairman of the Compensation Committee of the Board, sent a letter to certain POZEN stockholders to apprise them of certain undertakings of the Compensation Committee of the Board relating to POZEN’s annual meeting of stockholders, scheduled for June 4, 2014. POZEN Inc. (NASDAQ:POZN) shares advanced 5.75% in last trading session and ended the day on $9.20. POZN return on equity ratio is recorded as -27.40% and its return on assets is -23.40%. POZEN Inc. (NASDAQ:POZN) yearly performance is 122.22%.
Novartis AG (ADR) (NYSE:NVS) agreed to buy GlaxoSmithKline Plc’s cancer-drug business for as much as $16 billion, form a consumer-health venture with Glaxo and sell its animal-health unit to Eli Lilly (LLY) & Co. for $5.4 billion in an overhaul of the Swiss drugmaker. Novartis AG (ADR) (NYSE:NVS) shares moved up 0.93% in last trading session and was closed at $85.46 while trading in range of $84.50 – $85.50 – Novartis AG (ADR) (NYSE:NVS) year to date (YTD) performance is 9.90%.
RadNet, Inc. (NASDAQ:RDNT) a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, today announced the expiration and final results of its previously announced cash tender offer for any and all of its outstanding $200,0000,000 aggregate principal amount of 10 3/8% Senior Notes due 2018 (the “Notes”) and the related solicitation of consents to amend the indenture governing the Notes (the “Consent Solicitation”). RadNet Inc. (NASDAQ:RDNT) weekly performance is 13.76%. On last trading day company shares ended up $4.63. RadNet Inc. (NASDAQ:RDNT) distance from 50-day simple moving average (SMA50) is 66.83%. Analysts mean target price for the company is $3.63.
Leave a Reply